z-logo
open-access-imgOpen Access
Production of Multiple Growth Factors by a Newly Established Human Thyroid Carcinoma Cell Line
Author(s) -
Tohyama Kaoru,
Yoshida Yataro,
Ohashi Kensaku,
Sano Emiko,
Kobayashi Hisataka,
Endo Keigo,
Naruto Masanobu,
Nakamura Toru
Publication year - 1992
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1992.tb00080.x
Subject(s) - neutrophilia , granulocyte macrophage colony stimulating factor , cell culture , northern blot , eosinophil , biology , granulocyte , microbiology and biotechnology , cytokine , cancer research , immunology , gene expression , biochemistry , gene , genetics , asthma
A multiple growth factor‐producing tumor cell line (NIM‐1) was newly established from a patient with thyroid cancer and remarkable neutrophilia. NIM‐1 cells also caused severe neutrophilia in nude mice bearing tumors. NIM‐1‐conditioned medium (NIM‐1CM) contained activities that supported not only granulocyte, macrophage and eosinophil colony formation of human bone marrow cells but also the growth of colony‐stimulating factor (CSF)‐dependent cell lines, NFS60‐KX and TF‐1. Northern blot hybridization analysis revealed the constitutive expression of granulocyte‐CSF (G‐CSF), granulocyte/macrophage‐CSF (GM‐CSF) and interleukin(IL)‐6 mRNAs in NIM‐1 cells. Enzyme‐linked immunosorbent assays (ELISA) using NIM‐1CM also confirmed the production of IL‐la and a small amount of IL‐1β besides G‐CSF, GM‐CSF and IL‐6 in NIM‐1 cells. In addition, unexpected production of IL‐11 in NIM‐1 cells was detected by northern blot hybridization analysis and by bioassay using an IL‐11‐dependent cell line. Therefore, NIM‐1 cell line is shown to produce multiple cytokines including potentially megakaryopoietic growth factors such as GM‐CSF, IL‐6 and IL‐11.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here